Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2

Recruiting

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Transformed Lymphoma
Primary Mediastinal B-cell Lymphoma (PMBCL)
Central Nervous System Lymphoma

Interventions: Biological: zamtocabtagene autoleucel (MB-CART2019.1)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2021-03-11

Last Posted Date: 2024-04-26

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 110

Registration Number: NCT04792489

Locations: 🇺🇸
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United States
🇺🇸
Stanford University, Stanford, California, United States

and more 19 locations

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: KITE-222

First Posted Date: 2021-03-09

Last Posted Date: 2024-06-10

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 15

Registration Number: NCT04789408

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 6 locations

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Phase 1

Recruiting

Conditions: Fanconi Anemia

Interventions: Drug: JSP191
Device: CliniMACS Prodigy System
Biological: Depleted Stem Cell Transplant
Biological: Rabbit Anti-Thymoglobulin (rATG)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2021-03-05

Last Posted Date: 2023-12-14

Lead Sponsor: Porteus, Matthew, MD

Target Recruit Count: 12

Registration Number: NCT04784052

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Early Phase 1

Withdrawn

Conditions: Sickle Beta Thalassemia
Beta Thalassemia Major
Sickle Beta 0 Thalassemia
Sickle Beta Plus Thalassemia
Sickle Cell-SS Disease
Sickle Cell Disease

Interventions: Drug: Bortezomib
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Drug: Mycophenolate Mofetil
Procedure: Plasmapheresis
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2021-03-02

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04776850

A Phase 1 Study of ADI-001 in B Cell Malignancies

Phase 1

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Mantle-Cell
Marginal Zone Lymphoma
Primary Mediastinal B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Lymphoma, Follicular

Interventions: Genetic: ADI-001
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-02-03

Last Posted Date: 2024-04-10

Lead Sponsor: Adicet Therapeutics

Target Recruit Count: 78

Registration Number: NCT04735471

Locations: 🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 7 locations

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Phase 1

Suspended

Conditions: Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia

Interventions: Biological: Fully human anti CD19 CAR-T Cell Dose
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-02-01

Last Posted Date: 2025-01-06

Lead Sponsor: Benjamin Tomlinson

Target Recruit Count: 36

Registration Number: NCT04732845

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Rhabdoid Tumor
Wilms Tumor
Yolk Sac Tumor
Liver Cancer
Rhabdomyosarcoma
Liposarcoma

Interventions: Genetic: CARE T cells
Drug: Cytoxan
Drug: Fludara

First Posted Date: 2021-01-20

Last Posted Date: 2024-08-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT04715191

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myeloid Leukemia
Monocytic Leukemia

Interventions: Drug: Daratumumab/rHuPH20
Drug: FT538
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-01-19

Last Posted Date: 2024-10-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 9

Registration Number: NCT04714372

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Phase 2

Recruiting

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Busulfan
Drug: Cladribine
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Drug: Thiotepa
Drug: Venetoclax

First Posted Date: 2021-01-13

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 324

Registration Number: NCT04708054

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Biological: anti-BCMA CAR-T
Drug: Cyclophosphamid
Drug: Fludarabine

First Posted Date: 2021-01-13

Last Posted Date: 2023-02-06

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 25

Registration Number: NCT04706936

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy